GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ind-Swift Laboratories Ltd (NSE:INDSWFTLAB) » Definitions » EV-to-EBIT

Ind-Swift Laboratories (NSE:INDSWFTLAB) EV-to-EBIT : 7.57 (As of May. 15, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Ind-Swift Laboratories EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ind-Swift Laboratories's Enterprise Value is ₹14,343 Mil. Ind-Swift Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹1,893 Mil. Therefore, Ind-Swift Laboratories's EV-to-EBIT for today is 7.57.

The historical rank and industry rank for Ind-Swift Laboratories's EV-to-EBIT or its related term are showing as below:

NSE:INDSWFTLAB' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.38   Med: 1.53   Max: 15.21
Current: 7.57

During the past 13 years, the highest EV-to-EBIT of Ind-Swift Laboratories was 15.21. The lowest was -32.38. And the median was 1.53.

NSE:INDSWFTLAB's EV-to-EBIT is ranked better than
83.21% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.74 vs NSE:INDSWFTLAB: 7.57

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ind-Swift Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was ₹6,118 Mil. Ind-Swift Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹1,893 Mil. Ind-Swift Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 30.95%.


Ind-Swift Laboratories EV-to-EBIT Historical Data

The historical data trend for Ind-Swift Laboratories's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ind-Swift Laboratories EV-to-EBIT Chart

Ind-Swift Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.81 13.76 12.67 12.62 6.74

Ind-Swift Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.64 6.74 2.82 6.82 3.24

Competitive Comparison of Ind-Swift Laboratories's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ind-Swift Laboratories's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ind-Swift Laboratories's EV-to-EBIT falls into.



Ind-Swift Laboratories EV-to-EBIT Calculation

Ind-Swift Laboratories's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=14342.608/1893.477
=7.57

Ind-Swift Laboratories's current Enterprise Value is ₹14,343 Mil.
Ind-Swift Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,893 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ind-Swift Laboratories  (NSE:INDSWFTLAB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ind-Swift Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=1893.477/6118.448495
=30.95 %

Ind-Swift Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was ₹6,118 Mil.
Ind-Swift Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,893 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ind-Swift Laboratories EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ind-Swift Laboratories's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ind-Swift Laboratories (NSE:INDSWFTLAB) Business Description

Traded in Other Exchanges
Address
SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh, PB, IND, 160 101
Ind-Swift Laboratories Ltd is engaged in the business of active pharmaceutical ingredients (API). The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. Geographically, it derives a majority of revenue from Outside India.

Ind-Swift Laboratories (NSE:INDSWFTLAB) Headlines

No Headlines